Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Daniel Aaron Pollyea, Courtney Denton Dinardo, Stéphane de Botton, Eytan Stein, Gail J. Roboz, Alice S. Mims, Ronan T. Swords, Jessica K Altman, Robert Collins, Gabriel N. Mannis, Geoffrey L. Uy, William Bruce Donnellan, Arnaud Pigneux, Amir Tahmasb Fathi, Hua Liu, Bin Wu, Eyal C. Attar, Martin S. Tallman, Richard M. Stone, Hagop M. Kantarjian
Institutions: University of Colorado Anschutz, The University of Texas MD Anderson Cancer Center, Inserm, Institut Gustave Roussy, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, The Ohio State University Wexner Medical Center, Sylvester Comprehensive Cancer Center, Northwestern University, The University of Texas Southwestern Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center, Washington University in St. Louis, Sarah Cannon, Centre Hospitalier Universitaire de Bordeaux, Massachusetts General Hospital, Agios Pharmaceuticals (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891280799